 | • レポートコード：20QY06-07872 • 出版社/出版日：QYResearch / 2020年6月1日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、145ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥592,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥888,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,184,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、糖尿病性神経障害性鎮痛剤のグローバル市場について種類別（AZD-5213、塩酸クロニジン、塩酸デュロキセチンDR、E-52862、フィルグラスチム、GERPOOI、GRC-17536、その他）、用途別（クリニック、病院、その他）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・糖尿病性神経障害性鎮痛剤市場の概要 ・世界の主要地域別糖尿病性神経障害性鎮痛剤市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の糖尿病性神経障害性鎮痛剤市場規模2015-2026：種類別（AZD-5213、塩酸クロニジン、塩酸デュロキセチンDR、E-52862、フィルグラスチム、GERPOOI、GRC-17536、その他） ・世界の糖尿病性神経障害性鎮痛剤市場規模2015-2026：用途別（クリニック、病院、その他） ・糖尿病性神経障害性鎮痛剤の北米市場規模2015-2020 ・糖尿病性神経障害性鎮痛剤のヨーロッパ市場規模2015-2020 ・糖尿病性神経障害性鎮痛剤の中国市場規模2015-2020 ・糖尿病性神経障害性鎮痛剤の日本市場規模2015-2020 ・糖尿病性神経障害性鎮痛剤の東南アジア市場規模2015-2020 ・糖尿病性神経障害性鎮痛剤のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （Astellas Pharma Inc.、AstraZeneca Plc、BioDelivery Sciences International, Inc.、Boehringer Ingelheim GmbH、Daiichi Sankyo Company, Limited、Dong-A Socio Group、Eli Lilly and Company、Glenmark Pharmaceuticals Ltd.、Hydra Biosciences, Inc.、Immune Pharmaceuticals Inc.、Laboratorios Del Dr. Esteve S.A.、Lohocla Research Corporation、Mertiva AB、Novaremed、Pharmaleads、RAPID Pharmaceuticals AG、Relmada Therapeutics, Inc.、Sphaera Pharma Pvt. Ltd.、Theravasc, Inc.） ・糖尿病性神経障害性鎮痛剤の製造コスト分析 ・販売チャネル、流通業者、顧客 ・糖尿病性神経障害性鎮痛剤の市場動向・機会・課題 ・調査の結論 |
Market Analysis and Insights: Global Diabetic Neuropathic Pain Drug Market
The global Diabetic Neuropathic Pain Drug market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026.
Global Diabetic Neuropathic Pain Drug Scope and Market Size
The global Diabetic Neuropathic Pain Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Diabetic Neuropathic Pain Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Diabetic Neuropathic Pain Drug market is segmented into
AZD-5213
Clonidine Hydrochloride
Duloxetine Hydrochloride DR
E-52862
Filgrastim
GERPOOI
GRC-17536
Others
Segment by Application, the Diabetic Neuropathic Pain Drug market is segmented into
Clinic
Hospital
Others
The Diabetic Neuropathic Pain Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Diabetic Neuropathic Pain Drug market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Diabetic Neuropathic Pain Drug Market Share Analysis
Diabetic Neuropathic Pain Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Diabetic Neuropathic Pain Drug business, the date to enter into the Diabetic Neuropathic Pain Drug market, Diabetic Neuropathic Pain Drug product introduction, recent developments, etc.
The major vendors covered:
Astellas Pharma Inc.
AstraZeneca Plc
BioDelivery Sciences International, Inc.
Boehringer Ingelheim GmbH
Daiichi Sankyo Company, Limited
Dong-A Socio Group
Eli Lilly and Company
Glenmark Pharmaceuticals Ltd.
Hydra Biosciences, Inc.
Immune Pharmaceuticals Inc.
Laboratorios Del Dr. Esteve S.A.
Lohocla Research Corporation
Mertiva AB
Novaremed
Pharmaleads
RAPID Pharmaceuticals AG
Relmada Therapeutics, Inc.
Sphaera Pharma Pvt. Ltd.
Theravasc, Inc.
Table of Contents
1 Diabetic Neuropathic Pain Drug Market Overview
1.1 Diabetic Neuropathic Pain Drug Product Scope
1.2 Diabetic Neuropathic Pain Drug Segment by Type
1.2.1 Global Diabetic Neuropathic Pain Drug Sales by Type (2020-2026)
1.2.2 AZD-5213
1.2.3 Clonidine Hydrochloride
1.2.4 Duloxetine Hydrochloride DR
1.2.5 E-52862
1.2.6 Filgrastim
1.2.7 GERPOOI
1.2.8 GRC-17536
1.2.9 Others
1.3 Diabetic Neuropathic Pain Drug Segment by Application
1.3.1 Global Diabetic Neuropathic Pain Drug Sales Comparison by Application (2020-2026)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Diabetic Neuropathic Pain Drug Market Estimates and Forecasts (2015-2026)
1.4.1 Global Diabetic Neuropathic Pain Drug Sales Growth Rate (2015-2026)
1.4.2 Global Diabetic Neuropathic Pain Drug Revenue and Growth Rate (2015-2026)
1.4.3 Global Diabetic Neuropathic Pain Drug Price Trends (2015-2026)
2 Diabetic Neuropathic Pain Drug Estimate and Forecast by Region
2.1 Global Diabetic Neuropathic Pain Drug Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Diabetic Neuropathic Pain Drug Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2015-2020)
2.2.2 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2015-2020)
2.3 Global Diabetic Neuropathic Pain Drug Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Diabetic Neuropathic Pain Drug Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Diabetic Neuropathic Pain Drug Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Diabetic Neuropathic Pain Drug Estimates and Projections (2015-2026)
2.4.2 Europe Diabetic Neuropathic Pain Drug Estimates and Projections (2015-2026)
2.4.3 China Diabetic Neuropathic Pain Drug Estimates and Projections (2015-2026)
2.4.4 Japan Diabetic Neuropathic Pain Drug Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Diabetic Neuropathic Pain Drug Estimates and Projections (2015-2026)
2.4.6 India Diabetic Neuropathic Pain Drug Estimates and Projections (2015-2026)
3 Global Diabetic Neuropathic Pain Drug Competition Landscape by Players
3.1 Global Top Diabetic Neuropathic Pain Drug Players by Sales (2015-2020)
3.2 Global Top Diabetic Neuropathic Pain Drug Players by Revenue (2015-2020)
3.3 Global Diabetic Neuropathic Pain Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Neuropathic Pain Drug as of 2019)
3.4 Global Diabetic Neuropathic Pain Drug Average Price by Company (2015-2020)
3.5 Manufacturers Diabetic Neuropathic Pain Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Diabetic Neuropathic Pain Drug Players (Opinion Leaders)
4 Global Diabetic Neuropathic Pain Drug Market Size by Type
4.1 Global Diabetic Neuropathic Pain Drug Historic Market Review by Type (2015-2020)
4.1.1 Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
4.1.2 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2015-2020)
4.1.3 Global Diabetic Neuropathic Pain Drug Price by Type (2014-2020)
4.2 Global Diabetic Neuropathic Pain Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Diabetic Neuropathic Pain Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Diabetic Neuropathic Pain Drug Revenue Forecast by Type (2021-2026)
4.2.3 Global Diabetic Neuropathic Pain Drug Price Forecast by Type (2021-2026)
5 Global Diabetic Neuropathic Pain Drug Market Size by Application
5.1 Global Diabetic Neuropathic Pain Drug Historic Market Review by Application (2015-2020)
5.1.1 Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
5.1.2 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2015-2020)
5.1.3 Global Diabetic Neuropathic Pain Drug Price by Application (2015-2020)
5.2 Global Diabetic Neuropathic Pain Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Diabetic Neuropathic Pain Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Diabetic Neuropathic Pain Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Diabetic Neuropathic Pain Drug Price Forecast by Application (2021-2026)
3 North America Diabetic Neuropathic Pain Drug Market Facts & Figures
3.2 North America Diabetic Neuropathic Pain Drug Sales Market Share by Company (2015-2020)
3.3 North America Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
3.4 North America Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
4 Europe Diabetic Neuropathic Pain Drug Market Facts & Figures
4.2 Europe Diabetic Neuropathic Pain Drug Sales Market Share by Company (2015-2020)
4.3 Europe Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
4.4 Europe Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
5 China Diabetic Neuropathic Pain Drug Market Facts & Figures
5.2 China Diabetic Neuropathic Pain Drug Sales Market Share by Company (2015-2020)
5.3 China Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
5.4 China Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
6 Japan Diabetic Neuropathic Pain Drug Market Facts & Figures
6.2 Japan Diabetic Neuropathic Pain Drug Sales Market Share by Company (2015-2020)
6.3 Japan Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
6.4 Japan Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
7 Southeast Asia Diabetic Neuropathic Pain Drug Market Facts & Figures
7.2 Southeast Asia Diabetic Neuropathic Pain Drug Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
8 India Diabetic Neuropathic Pain Drug Market Facts & Figures
8.2 India Diabetic Neuropathic Pain Drug Sales Market Share by Company (2015-2020)
8.3 India Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
8.4 India Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Diabetic Neuropathic Pain Drug Business
12.1 Astellas Pharma Inc.
12.1.1 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Corporation Information
12.1.2 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.1.3 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Products Offered
12.1.5 Astellas Pharma Inc. Recent Development
12.2 AstraZeneca Plc
12.2.1 AstraZeneca Plc Diabetic Neuropathic Pain Drug Corporation Information
12.2.2 AstraZeneca Plc Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.2.3 AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.2.4 AstraZeneca Plc Diabetic Neuropathic Pain Drug Products Offered
12.2.5 AstraZeneca Plc Recent Development
12.3 BioDelivery Sciences International, Inc.
12.3.1 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Corporation Information
12.3.2 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.3.3 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.3.4 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Products Offered
12.3.5 BioDelivery Sciences International, Inc. Recent Development
12.4 Boehringer Ingelheim GmbH
12.4.1 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Corporation Information
12.4.2 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.4.3 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Products Offered
12.4.5 Boehringer Ingelheim GmbH Recent Development
12.5 Daiichi Sankyo Company, Limited
12.5.1 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Corporation Information
12.5.2 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.5.3 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Products Offered
12.5.5 Daiichi Sankyo Company, Limited Recent Development
12.6 Dong-A Socio Group
12.6.1 Dong-A Socio Group Diabetic Neuropathic Pain Drug Corporation Information
12.6.2 Dong-A Socio Group Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.6.3 Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Dong-A Socio Group Diabetic Neuropathic Pain Drug Products Offered
12.6.5 Dong-A Socio Group Recent Development
12.7 Eli Lilly and Company
12.7.1 Eli Lilly and Company Diabetic Neuropathic Pain Drug Corporation Information
12.7.2 Eli Lilly and Company Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.7.3 Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Eli Lilly and Company Diabetic Neuropathic Pain Drug Products Offered
12.7.5 Eli Lilly and Company Recent Development
12.8 Glenmark Pharmaceuticals Ltd.
12.8.1 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Corporation Information
12.8.2 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.8.3 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Products Offered
12.8.5 Glenmark Pharmaceuticals Ltd. Recent Development
12.9 Hydra Biosciences, Inc.
12.9.1 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Corporation Information
12.9.2 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.9.3 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Products Offered
12.9.5 Hydra Biosciences, Inc. Recent Development
12.10 Immune Pharmaceuticals Inc.
12.10.1 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Corporation Information
12.10.2 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.10.3 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Products Offered
12.10.5 Immune Pharmaceuticals Inc. Recent Development
12.11 Laboratorios Del Dr. Esteve S.A.
12.11.1 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Corporation Information
12.11.2 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.11.3 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Products Offered
12.11.5 Laboratorios Del Dr. Esteve S.A. Recent Development
12.12 Lohocla Research Corporation
12.12.1 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Corporation Information
12.12.2 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.12.3 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Products Offered
12.12.5 Lohocla Research Corporation Recent Development
12.13 Mertiva AB
12.13.1 Mertiva AB Diabetic Neuropathic Pain Drug Corporation Information
12.13.2 Mertiva AB Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.13.3 Mertiva AB Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Mertiva AB Diabetic Neuropathic Pain Drug Products Offered
12.13.5 Mertiva AB Recent Development
12.14 Novaremed
12.14.1 Novaremed Diabetic Neuropathic Pain Drug Corporation Information
12.14.2 Novaremed Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.14.3 Novaremed Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Novaremed Diabetic Neuropathic Pain Drug Products Offered
12.14.5 Novaremed Recent Development
12.15 Pharmaleads
12.15.1 Pharmaleads Diabetic Neuropathic Pain Drug Corporation Information
12.15.2 Pharmaleads Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.15.3 Pharmaleads Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Pharmaleads Diabetic Neuropathic Pain Drug Products Offered
12.15.5 Pharmaleads Recent Development
12.16 RAPID Pharmaceuticals AG
12.16.1 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Corporation Information
12.16.2 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.16.3 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.16.4 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Products Offered
12.16.5 RAPID Pharmaceuticals AG Recent Development
12.17 Relmada Therapeutics, Inc.
12.17.1 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Corporation Information
12.17.2 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.17.3 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.17.4 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Products Offered
12.17.5 Relmada Therapeutics, Inc. Recent Development
12.18 Sphaera Pharma Pvt. Ltd.
12.18.1 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Corporation Information
12.18.2 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.18.3 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.18.4 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Products Offered
12.18.5 Sphaera Pharma Pvt. Ltd. Recent Development
12.19 Theravasc, Inc.
12.19.1 Theravasc, Inc. Diabetic Neuropathic Pain Drug Corporation Information
12.19.2 Theravasc, Inc. Diabetic Neuropathic Pain Drug Business Overview and Total Revenue
12.19.3 Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue and Gross Margin (2015-2020)
12.19.4 Theravasc, Inc. Diabetic Neuropathic Pain Drug Products Offered
12.19.5 Theravasc, Inc. Recent Development
13 Diabetic Neuropathic Pain Drug Manufacturing Cost Analysis
13.1 Diabetic Neuropathic Pain Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Diabetic Neuropathic Pain Drug
13.4 Diabetic Neuropathic Pain Drug Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Diabetic Neuropathic Pain Drug Distributors List
14.3 Diabetic Neuropathic Pain Drug Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) Growth Rate by Type (2020-2026)
Table 2. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) Comparison by Application (2020-2026)
Table 3. Global Market Diabetic Neuropathic Pain Drug Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) by Region (2015-2020)
Table 5. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2015-2020)
Table 6. Global Diabetic Neuropathic Pain Drug Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Diabetic Neuropathic Pain Drug Revenue Share by Region (2015-2020)
Table 8. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) Forecast by Region (2021-2026)
Table 9. Global Diabetic Neuropathic Pain Drug Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Diabetic Neuropathic Pain Drug Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Diabetic Neuropathic Pain Drug Revenue Share Forecast by Region (2021-2026)
Table 12. Global Diabetic Neuropathic Pain Drug (K Pcs) of Key Companies (2015-2020)
Table 13. Global Diabetic Neuropathic Pain Drug Sales Share by Company (2015-2020)
Table 14. Global Diabetic Neuropathic Pain Drug Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Diabetic Neuropathic Pain Drug Revenue Share by Company (2015-2020)
Table 16. Global Diabetic Neuropathic Pain Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Neuropathic Pain Drug as of 2019)
Table 17. Global Diabetic Neuropathic Pain Drug Average Price (USD/Pcs) of Key Company (2015-2020)
Table 18. Manufacturers Diabetic Neuropathic Pain Drug Manufacturing Sites and Area Served
Table 19. Manufacturers Diabetic Neuropathic Pain Drug Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Diabetic Neuropathic Pain Drug Players
Table 22. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) by Type (2015-2020)
Table 23. Global Diabetic Neuropathic Pain Drug Sales Share by Type (2015-2020)
Table 24. Global Diabetic Neuropathic Pain Drug Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Diabetic Neuropathic Pain Drug Price (K Pcs) by Type (2015-2020)
Table 26. Global Diabetic Neuropathic Pain Drug Sales Share by Type (2021-2026)
Table 27. Global Diabetic Neuropathic Pain Drug Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Diabetic Neuropathic Pain Drug Revenue Share by Type (2021-2026)
Table 29. Global Diabetic Neuropathic Pain Drug Price (K Pcs) by Type (2021-2026)
Table 30. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) by Application (2015-2020)
Table 31. Global Diabetic Neuropathic Pain Drug Sales Share by Application (2015-2020)
Table 32. Global Diabetic Neuropathic Pain Drug Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Diabetic Neuropathic Pain Drug Price (K Pcs) by Application (2015-2020)
Table 34. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) by Application (2021-2026)
Table 35. Global Diabetic Neuropathic Pain Drug Sales Share by Application (2021-2026)
Table 36. Global Diabetic Neuropathic Pain Drug Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Diabetic Neuropathic Pain Drug Revenue Share by Application (2021-2026)
Table 38. Global Diabetic Neuropathic Pain Drug Price (K Pcs) by Application (2021-2026)
Table 39. United States Diabetic Neuropathic Pain Drug Sales (K Pcs) by Company (2015-2020)
Table 40. United States Diabetic Neuropathic Pain Drug Sales Market Share by Company (2015-2020)
Table 41. United States Diabetic Neuropathic Pain Drug Sales (K Pcs) by Type (2015-2020)
Table 42. United States Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
Table 43. United States Diabetic Neuropathic Pain Drug Sales (K Pcs) by Application (2015-2020)
Table 44. United States Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
Table 45. Europe Diabetic Neuropathic Pain Drug Sales (K Pcs) by Company (2015-2020)
Table 46. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Company (2015-2020)
Table 47. Europe Diabetic Neuropathic Pain Drug Sales (K Pcs) by Type (2015-2020)
Table 48. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
Table 49. Europe Diabetic Neuropathic Pain Drug Sales (K Pcs) by Application (2015-2020)
Table 50. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
Table 51. China Diabetic Neuropathic Pain Drug Sales (K Pcs) by Company (2015-2020)
Table 52. China Diabetic Neuropathic Pain Drug Sales Market Share by Company (2015-2020)
Table 53. China Diabetic Neuropathic Pain Drug Sales (K Pcs) by Type (2015-2020)
Table 54. China Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
Table 55. China Diabetic Neuropathic Pain Drug Sales (K Pcs) by Application (2015-2020)
Table 56. China Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
Table 57. Japan Diabetic Neuropathic Pain Drug Sales (K Pcs) by Company (2015-2020)
Table 58. Japan Diabetic Neuropathic Pain Drug Sales Market Share by Company (2015-2020)
Table 59. Japan Diabetic Neuropathic Pain Drug Sales (K Pcs) by Type (2015-2020)
Table 60. Japan Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
Table 61. Japan Diabetic Neuropathic Pain Drug Sales (K Pcs) by Application (2015-2020)
Table 62. Japan Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Diabetic Neuropathic Pain Drug Sales (K Pcs) by Company (2015-2020)
Table 64. Southeast Asia Diabetic Neuropathic Pain Drug Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Diabetic Neuropathic Pain Drug Sales (K Pcs) by Type (2015-2020)
Table 66. Southeast Asia Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Diabetic Neuropathic Pain Drug Sales (K Pcs) by Type (2015-2020)
Table 68. Southeast Asia Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
Table 69. India Diabetic Neuropathic Pain Drug Sales (K Pcs) by Company (2015-2020)
Table 70. India Diabetic Neuropathic Pain Drug Sales Market Share by Company (2015-2020)
Table 71. India Diabetic Neuropathic Pain Drug Sales (K Pcs) by Type (2015-2020)
Table 72. India Diabetic Neuropathic Pain Drug Sales Market Share by Type (2015-2020)
Table 73. India Diabetic Neuropathic Pain Drug Sales (K Pcs) by Application (2015-2020)
Table 74. India Diabetic Neuropathic Pain Drug Sales Market Share by Application (2015-2020)
Table 75. Astellas Pharma Inc. Corporation Information
Table 76. Astellas Pharma Inc. Description and Business Overview
Table 77. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product
Table 79. Astellas Pharma Inc. Recent Development
Table 80. AstraZeneca Plc Corporation Information
Table 81. AstraZeneca Plc Description and Business Overview
Table 82. AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. AstraZeneca Plc Diabetic Neuropathic Pain Drug Product
Table 84. AstraZeneca Plc Recent Development
Table 85. BioDelivery Sciences International, Inc. Corporation Information
Table 86. BioDelivery Sciences International, Inc. Description and Business Overview
Table 87. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product
Table 89. BioDelivery Sciences International, Inc. Recent Development
Table 90. Boehringer Ingelheim GmbH Corporation Information
Table 91. Boehringer Ingelheim GmbH Description and Business Overview
Table 92. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product
Table 94. Boehringer Ingelheim GmbH Recent Development
Table 95. Daiichi Sankyo Company, Limited Corporation Information
Table 96. Daiichi Sankyo Company, Limited Description and Business Overview
Table 97. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product
Table 99. Daiichi Sankyo Company, Limited Recent Development
Table 100. Dong-A Socio Group Corporation Information
Table 101. Dong-A Socio Group Description and Business Overview
Table 102. Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. Dong-A Socio Group Diabetic Neuropathic Pain Drug Product
Table 104. Dong-A Socio Group Recent Development
Table 105. Eli Lilly and Company Corporation Information
Table 106. Eli Lilly and Company Description and Business Overview
Table 107. Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Eli Lilly and Company Diabetic Neuropathic Pain Drug Product
Table 109. Eli Lilly and Company Recent Development
Table 110. Glenmark Pharmaceuticals Ltd. Corporation Information
Table 111. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. Glenmark Pharmaceuticals Ltd. Description and Business Overview
Table 113. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product
Table 114. Glenmark Pharmaceuticals Ltd. Recent Development
Table 115. Hydra Biosciences, Inc. Corporation Information
Table 116. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 117. Hydra Biosciences, Inc. Description and Business Overview
Table 118. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product
Table 119. Hydra Biosciences, Inc. Recent Development
Table 120. Immune Pharmaceuticals Inc. Corporation Information
Table 121. Immune Pharmaceuticals Inc. Description and Business Overview
Table 122. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product
Table 124. Immune Pharmaceuticals Inc. Recent Development
Table 125. Laboratorios Del Dr. Esteve S.A. Corporation Information
Table 126. Laboratorios Del Dr. Esteve S.A. Description and Business Overview
Table 127. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 128. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product
Table 129. Laboratorios Del Dr. Esteve S.A. Recent Development
Table 130. Lohocla Research Corporation Corporation Information
Table 131. Lohocla Research Corporation Description and Business Overview
Table 132. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 133. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product
Table 134. Lohocla Research Corporation Recent Development
Table 135. Mertiva AB Corporation Information
Table 136. Mertiva AB Description and Business Overview
Table 137. Mertiva AB Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 138. Mertiva AB Diabetic Neuropathic Pain Drug Product
Table 139. Mertiva AB Recent Development
Table 140. Novaremed Corporation Information
Table 141. Novaremed Description and Business Overview
Table 142. Novaremed Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 143. Novaremed Diabetic Neuropathic Pain Drug Product
Table 144. Novaremed Recent Development
Table 145. Pharmaleads Corporation Information
Table 146. Pharmaleads Description and Business Overview
Table 147. Pharmaleads Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 148. Pharmaleads Diabetic Neuropathic Pain Drug Product
Table 149. Pharmaleads Recent Development
Table 150. RAPID Pharmaceuticals AG Corporation Information
Table 151. RAPID Pharmaceuticals AG Description and Business Overview
Table 152. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 153. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product
Table 154. RAPID Pharmaceuticals AG Recent Development
Table 155. Relmada Therapeutics, Inc. Corporation Information
Table 156. Relmada Therapeutics, Inc. Description and Business Overview
Table 157. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 158. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product
Table 159. Relmada Therapeutics, Inc. Recent Development
Table 160. Sphaera Pharma Pvt. Ltd. Corporation Information
Table 161. Sphaera Pharma Pvt. Ltd. Description and Business Overview
Table 162. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 163. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product
Table 164. Sphaera Pharma Pvt. Ltd. Recent Development
Table 165. Theravasc, Inc. Corporation Information
Table 166. Theravasc, Inc. Description and Business Overview
Table 167. Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 168. Theravasc, Inc. Diabetic Neuropathic Pain Drug Product
Table 169. Theravasc, Inc. Recent Development
Table 170. Production Base and Market Concentration Rate of Raw Material
Table 171. Key Suppliers of Raw Materials
Table 172. Diabetic Neuropathic Pain Drug Distributors List
Table 173. Diabetic Neuropathic Pain Drug Customers List
Table 174. Market Key Trends
Table 175. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 176. Key Challenges
Table 177. Research Programs/Design for This Report
Table 178. Key Data Information from Secondary Sources
Table 179. Key Data Information from Primary Sources
List of Figures
Figure 1. Diabetic Neuropathic Pain Drug Product Picture
Figure 2. Global Diabetic Neuropathic Pain Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Diabetic Neuropathic Pain Drug Market Share by Application in 2020 & 2026
Figure 6. Clinic Examples
Figure 7. Hospital Examples
Figure 8. Others Examples
Figure 9. Global Diabetic Neuropathic Pain Drug Sales (K Pcs) Growth Rate (2015-2026)
Figure 10. Global Diabetic Neuropathic Pain Drug Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Diabetic Neuropathic Pain Drug Price Trends Growth Rate (2015-2026) (USD/Pcs)
Figure 12. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Diabetic Neuropathic Pain Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Diabetic Neuropathic Pain Drug Sales (K Pcs) Growth Rate (2015-2026)
Figure 16. Europe Diabetic Neuropathic Pain Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Diabetic Neuropathic Pain Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Diabetic Neuropathic Pain Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Diabetic Neuropathic Pain Drug Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Diabetic Neuropathic Pain Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Diabetic Neuropathic Pain Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Diabetic Neuropathic Pain Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Diabetic Neuropathic Pain Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Diabetic Neuropathic Pain Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Diabetic Neuropathic Pain Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Diabetic Neuropathic Pain Drug Players Market Share by Revenue in Diabetic Neuropathic Pain Drug 2015 & 2019
Figure 27. Diabetic Neuropathic Pain Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Diabetic Neuropathic Pain Drug Revenue Share by Type (2015-2020)
Figure 29. Global Diabetic Neuropathic Pain Drug Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Diabetic Neuropathic Pain Drug Revenue Share by Application (2015-2020)
Figure 31. Global Diabetic Neuropathic Pain Drug Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Diabetic Neuropathic Pain Drug Sales Market Share by Type in 2019
Figure 33. United States Diabetic Neuropathic Pain Drug Sales Market Share by Type in 2019
Figure 34. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Company in 2019
Figure 35. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Type in 2019
Figure 36. Europe Diabetic Neuropathic Pain Drug Sales Market Share by Application in 2019
Figure 37. China Diabetic Neuropathic Pain Drug Sales Market Share by Company in 2019
Figure 38. China Diabetic Neuropathic Pain Drug Sales Market Share by Type in 2019
Figure 39. China Diabetic Neuropathic Pain Drug Sales Market Share by Application in 2019
Figure 40. Japan Diabetic Neuropathic Pain Drug Sales Market Share by Company in 2019
Figure 41. Japan Diabetic Neuropathic Pain Drug Sales Market Share by Type in 2019
Figure 42. Japan Diabetic Neuropathic Pain Drug Sales Market Share by Application in 2019
Figure 43. Southeast Asia Diabetic Neuropathic Pain Drug Sales Market Share by Company in 2019
Figure 44. Southeast Asia Diabetic Neuropathic Pain Drug Sales Market Share by Type in 2019
Figure 45. Southeast Asia Diabetic Neuropathic Pain Drug Sales Market Share by Application in 2019
Figure 46. India Diabetic Neuropathic Pain Drug Sales Market Share by Company in 2019
Figure 47. India Diabetic Neuropathic Pain Drug Sales Market Share by Type in 2019
Figure 48. India Diabetic Neuropathic Pain Drug Sales Market Share by Application in 2019
Figure 49. Astellas Pharma Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. AstraZeneca Plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. BioDelivery Sciences International, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Boehringer Ingelheim GmbH Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Daiichi Sankyo Company, Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Dong-A Socio Group Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Glenmark Pharmaceuticals Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Hydra Biosciences, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Immune Pharmaceuticals Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Laboratorios Del Dr. Esteve S.A. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Lohocla Research Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Mertiva AB Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Novaremed Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Pharmaleads Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. RAPID Pharmaceuticals AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Relmada Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Sphaera Pharma Pvt. Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 67. Theravasc, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. Key Raw Materials Price Trend
Figure 69. Manufacturing Cost Structure of Diabetic Neuropathic Pain Drug
Figure 70. Manufacturing Process Analysis of Diabetic Neuropathic Pain Drug
Figure 71. Diabetic Neuropathic Pain Drug Industrial Chain Analysis
Figure 72. Channels of Distribution
Figure 73. Distributors Profiles
Figure 74. Porter's Five Forces Analysis
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
変形性股関節症鎮痛剤の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Hip Osteoarthritis Pain Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 5.3% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Hip Osteoarthri…- 脊椎変形性関節症用鎮痛剤の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Spine Osteoarthritis Pain Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 5.5% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Spine Osteoar…
- 糖尿病性網膜症薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Diabetic Retinopathy Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Diabetic Retinopat…
- 糖尿病性穿刺器具の世界市場レポート2020 Diabetes is a global epidemic affecting an estimated 382 million people worldwide. The WHO projects that diabetes will be the 7th leading cause of death by 2030. An estimated 4 million people die annually from the complications associated with diabetes. Therefore, if the current trend associated wit…
- 黄斑変性症（AMD）及び糖尿病性網膜症（DR）薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx mil…